B
Bullisch
Bullisch · 25%TAK
$18.07
Szenariopreis
$19.670
+0.222 (+1.13%)Zum Schluss
Loading chart…
- Hoch
- 19.705
- Eröffnung
- 19.670
- Volumengewichteter Durchschnittskurs
- 19.65
- Volumen
- 2.83M
- Marktkap.
- 40.51B
- Tief
- 19.561
- Umsatz
- 55.55M
- EV/EBITDA, TTM
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
KI-Analyse of Takeda Pharmaceutical Co Ltd (TAK)
KaufenTakeda Pharmaceutical Co Ltd is a good buy right now, with a current price of 19.67 and a strong year-to-date change of +25.93%. The stock has shown resilience with a 5-day change of +5.02%, and the upcoming FDA decision on Zasocitinib could further boost its prospects. However, the main risk lies in its recent earnings volatility, as seen in the last quarter where the EPS was reported at 0.48, exceeding the estimate of 0.41, but still reflecting fluctuations in net income.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Takeda Pharmaceutical Co Ltd (TAK) beträgt 11.47, verglichen mit dem 5-Jahres-Durchschnitt von 25.23.
Alphio-AI-Kursszenarien für TAK
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
5.010-15NewsfilterORZEYFUL Approved for Launch in Japan and China
- 9.009-30Newsfilter
Zasocitinib Shows Superiority in Psoriasis Treatment
- 9.009-22Newsfilter
Takeda Unveils New Data at ESMO Congress on Cancer Treatments
- 8.509-18Newsfilter
Takeda Awards $22.2 Million to 2026 Global CSR Partners
- 8.509-14Newsfilter
Takeda's Zasocitinib Receives FDA Priority Review for Psoriasis
TAK FAQ – beantwortet von Alphio AI
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd is a good buy right now, with a current price of 19.67 and a strong year-to-date change of +25.93%. The stock has shown resilience with a 5-day change of +5.02%, and the upcoming FDA decision on Zasocitinib could further boost its prospects. However, the main risk lies in its recent earnings volatility, as seen in the last quarter where the EPS was reported at 0.48, exceeding the estimate of 0.41, but still reflecting fluctuations in net income.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.